SCHEDULE 13G: Venrock Funds Disclose 9.9% Passive Stake in Crescent Biopharma, Inc.

Venrock Healthcare Capital Partners and affiliated entities have disclosed a passive 9.9% beneficial ownership stake in Crescent Biopharma, Inc., primarily through ordinary shares and pre-funded warrants.

Summary

• Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh collectively reported beneficial ownership of 1,391,196 ordinary shares of Crescent Biopharma, Inc.
• This aggregate ownership represents 9.9% of the company's outstanding ordinary shares, rounded down from 9.99% due to EDGAR filing system limitations.
• The ownership includes 273,808 ordinary shares and pre-funded warrants exercisable for up to 107,374 ordinary shares held by VHCP III.
• VHCP Co-Investment III holds 27,381 ordinary shares and pre-funded warrants exercisable for up to 10,737 ordinary shares.
• VHCP EG holds 1,056,676 ordinary shares and pre-funded warrants exercisable for up to 414,377 ordinary shares.
• The pre-funded warrants contain a 'Beneficial Ownership Blocker' provision, preventing exercise if it would result in beneficial ownership exceeding 9.99% of the outstanding ordinary shares.
• The beneficial ownership percentage is calculated based on 13,892,562 outstanding ordinary shares as of June 13, 2025, plus 33,331 ordinary shares issuable upon the exercise of the pre-funded warrants.
• The reporting persons explicitly state that the securities were not acquired and are not held for the purpose or effect of changing or influencing the control of Crescent Biopharma, Inc.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While a Schedule 13G is a factual disclosure, the establishment of a significant passive stake by a reputable healthcare-focused investment firm like Venrock can be viewed favorably by the market as a vote of confidence in the company's prospects.

Positives

• The disclosure of a significant 9.9% stake by Venrock Healthcare Capital Partners, a reputable investment firm, can be interpreted as a vote of confidence in Crescent Biopharma, Inc.'s long-term prospects.
• The investment is explicitly stated to be passive, indicating that the reporting persons do not intend to seek control or influence the management of the issuer, which can provide stability.

Risks

• The 'Beneficial Ownership Blocker' in the pre-funded warrants limits the reporting persons' ability to exercise warrants if it would result in their beneficial ownership exceeding 9.99% of the outstanding ordinary shares, potentially capping their upside from these specific instruments.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding Crescent Biopharma, Inc.'s future operations or financial performance, as it is a disclosure of beneficial ownership.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This Schedule 13G filing indicates a significant investment by a specialized healthcare capital firm, Venrock, into Crescent Biopharma, Inc. This type of institutional investment is common in the biopharma sector, where capital-intensive research and development often attract venture capital and private equity firms seeking long-term growth opportunities. The passive nature of the stake suggests a belief in the company's existing strategy rather than an intent for active intervention.

Comparison to Industry Standards

• The filing of a Schedule 13G by an institutional investor like Venrock Healthcare Capital Partners is a standard regulatory requirement when beneficial ownership of a public company's stock exceeds 5% and the intent is passive.
• The 'Beneficial Ownership Blocker' provision in the pre-funded warrants is a common mechanism used by investors to avoid triggering certain regulatory thresholds or control-related provisions, ensuring compliance with passive investment rules.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake may instill confidence and potentially influence market perception positively.
• Management: The passive nature of the investment indicates no immediate intent by the reporting persons to influence or change company management or strategy.

Next Steps

• The reporting persons will continue to file amendments to this Schedule 13G if there are material changes to their beneficial ownership or investment intent, as required by SEC regulations.

Key Dates

Recommendation

Keywords

Crescent Biopharma, Venrock Healthcare Capital Partners, Schedule 13G, Beneficial Ownership, Ordinary Shares, Pre-Funded Warrants, SEC Filing, Institutional Investor, Biopharma, Healthcare Investment